AR119617A1 - Síntesis de un inhibidor de calicreína plasmática a escala de proceso - Google Patents
Síntesis de un inhibidor de calicreína plasmática a escala de procesoInfo
- Publication number
- AR119617A1 AR119617A1 ARP200102248A ARP200102248A AR119617A1 AR 119617 A1 AR119617 A1 AR 119617A1 AR P200102248 A ARP200102248 A AR P200102248A AR P200102248 A ARP200102248 A AR P200102248A AR 119617 A1 AR119617 A1 AR 119617A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- kallicerein
- inhibitor
- synthesis
- formula
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962883396P | 2019-08-06 | 2019-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119617A1 true AR119617A1 (es) | 2021-12-29 |
Family
ID=74504082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102248A AR119617A1 (es) | 2019-08-06 | 2020-08-06 | Síntesis de un inhibidor de calicreína plasmática a escala de proceso |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12503443B2 (https=) |
| EP (1) | EP4010320A4 (https=) |
| JP (1) | JP7626751B2 (https=) |
| KR (1) | KR102928815B1 (https=) |
| CN (1) | CN114206839B (https=) |
| AR (1) | AR119617A1 (https=) |
| AU (1) | AU2020324422B2 (https=) |
| BR (1) | BR112022002060A2 (https=) |
| CA (1) | CA3149176A1 (https=) |
| CL (2) | CL2022000264A1 (https=) |
| CO (1) | CO2022002392A2 (https=) |
| CR (1) | CR20220092A (https=) |
| DO (1) | DOP2022000027A (https=) |
| EC (1) | ECSP22016209A (https=) |
| GE (2) | GEAP202515893A (https=) |
| IL (1) | IL290113B2 (https=) |
| JO (1) | JOP20220021A1 (https=) |
| MX (1) | MX2022001608A (https=) |
| PE (1) | PE20221009A1 (https=) |
| PH (1) | PH12022550221A1 (https=) |
| PY (1) | PY2042865A (https=) |
| TN (1) | TN2022000028A1 (https=) |
| TW (1) | TWI881995B (https=) |
| UA (1) | UA130182C2 (https=) |
| UY (1) | UY38826A (https=) |
| WO (1) | WO2021026182A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| CN114206839B (zh) | 2019-08-06 | 2025-03-07 | 拜奥克里斯特制药公司 | 血浆激肽释放酶抑制剂的生产规模合成 |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| DE60034447T2 (de) | 2000-08-11 | 2008-02-14 | Wilex Ag | Nicht-kovalente Urokinase-und Angiogenese-Inhibitoren |
| US7038057B2 (en) * | 2001-08-13 | 2006-05-02 | E.I. Du Pont De Nemours And Company | Substituted 1H-dihydropyrazoles, their preparation and use |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| MX2011006319A (es) * | 2008-12-18 | 2011-06-24 | Bayer Cropscience Ag | Amidas del acido antranilico sustituidas con tetrazol como plaguicidas. |
| CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| EP2909181B1 (en) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| CN114206839B (zh) | 2019-08-06 | 2025-03-07 | 拜奥克里斯特制药公司 | 血浆激肽释放酶抑制剂的生产规模合成 |
-
2020
- 2020-08-05 CN CN202080055475.4A patent/CN114206839B/zh active Active
- 2020-08-05 TW TW109126552A patent/TWI881995B/zh active
- 2020-08-05 IL IL290113A patent/IL290113B2/en unknown
- 2020-08-05 AU AU2020324422A patent/AU2020324422B2/en active Active
- 2020-08-05 JP JP2022506947A patent/JP7626751B2/ja active Active
- 2020-08-05 JO JOP/2022/0021A patent/JOP20220021A1/ar unknown
- 2020-08-05 GE GEAP202515893A patent/GEAP202515893A/en unknown
- 2020-08-05 WO PCT/US2020/044921 patent/WO2021026182A1/en not_active Ceased
- 2020-08-05 EP EP20850499.3A patent/EP4010320A4/en active Pending
- 2020-08-05 CR CR20220092A patent/CR20220092A/es unknown
- 2020-08-05 PE PE2022000188A patent/PE20221009A1/es unknown
- 2020-08-05 TN TNP/2022/000028A patent/TN2022000028A1/en unknown
- 2020-08-05 UA UAA202200914A patent/UA130182C2/uk unknown
- 2020-08-05 US US17/632,585 patent/US12503443B2/en active Active
- 2020-08-05 PH PH1/2022/550221A patent/PH12022550221A1/en unknown
- 2020-08-05 CA CA3149176A patent/CA3149176A1/en active Pending
- 2020-08-05 KR KR1020227003932A patent/KR102928815B1/ko active Active
- 2020-08-05 BR BR112022002060A patent/BR112022002060A2/pt unknown
- 2020-08-05 MX MX2022001608A patent/MX2022001608A/es unknown
- 2020-08-05 GE GEAP202015893A patent/GEP20257777B/en unknown
- 2020-08-06 PY PY202002042865A patent/PY2042865A/es unknown
- 2020-08-06 AR ARP200102248A patent/AR119617A1/es unknown
- 2020-08-06 UY UY0001038826A patent/UY38826A/es unknown
-
2022
- 2022-02-01 CL CL2022000264A patent/CL2022000264A1/es unknown
- 2022-02-03 DO DO2022000027A patent/DOP2022000027A/es unknown
- 2022-02-28 CO CONC2022/0002392A patent/CO2022002392A2/es unknown
- 2022-03-03 EC ECSENADI202216209A patent/ECSP22016209A/es unknown
-
2023
- 2023-03-30 CL CL2023000942A patent/CL2023000942A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119617A1 (es) | Síntesis de un inhibidor de calicreína plasmática a escala de proceso | |
| AR114631A1 (es) | Métodos e intermedios para preparar compuestos de piridina | |
| ECSP22057865A (es) | Inhibidores de formas mutantes de egfr | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| MX2018003318A (es) | Derivado de biarilo y medicamento que contiene el mismo. | |
| CL2021002110A1 (es) | Hidroxipiridoxazepinas como activadores de nrf2. | |
| CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
| MX2019010642A (es) | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. | |
| PE20231308A1 (es) | Proceso e intermedios para preparar un inhibidor de jak1 | |
| CL2024001364A1 (es) | Inhibidores de pi3k-alfa y métodos para su producción y uso | |
| MX2025003091A (es) | Metodo para producir derivado de heterociclideno acetamida | |
| AR126196A1 (es) | Proceso para preparar inhibidores de egfr | |
| AR113958A1 (es) | Macrociclos a como inhibidores de pde1 | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
| AR116951A1 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| BR112022003171A2 (pt) | Processo para a síntese de compostos de pirazolidinona | |
| CL2023003979A1 (es) | Inhibidores de las transglutaminasas | |
| CL2018003872A1 (es) | Sales cristalinas del inhibidor de inmunoproteasoma de péptido epoxicetona. | |
| PE20230183A1 (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina | |
| CL2024003627A1 (es) | Proceso para preparar una formulación líquida de una sal de amonio de glufosinato o isómeros del mismo. | |
| AR120598A1 (es) | Proceso para la síntesis de un 2-(5-isoxazolil)-fenol | |
| PE20141794A1 (es) | N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas | |
| MX2023014302A (es) | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. | |
| CL2019000294A1 (es) | Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma. |